KR920000662A - 알루미늄 티타네이트를 기본으로 하는 소결된 세라믹 재료, 이의 제조방법 및 용도 - Google Patents

알루미늄 티타네이트를 기본으로 하는 소결된 세라믹 재료, 이의 제조방법 및 용도 Download PDF

Info

Publication number
KR920000662A
KR920000662A KR1019910010287A KR910010287A KR920000662A KR 920000662 A KR920000662 A KR 920000662A KR 1019910010287 A KR1019910010287 A KR 1019910010287A KR 910010287 A KR910010287 A KR 910010287A KR 920000662 A KR920000662 A KR 920000662A
Authority
KR
South Korea
Prior art keywords
ceramic material
sintered ceramic
material according
weight
sintered
Prior art date
Application number
KR1019910010287A
Other languages
English (en)
Other versions
KR0186008B1 (ko
Inventor
프로이덴베르크 베른하르트
세이어 요하네스
구겔 에른스트
Original Assignee
롤프 브라운; 귄터 슈마허
바이엘 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 롤프 브라운; 귄터 슈마허, 바이엘 아크티엔게젤샤프트 filed Critical 롤프 브라운; 귄터 슈마허
Publication of KR920000662A publication Critical patent/KR920000662A/ko
Application granted granted Critical
Publication of KR0186008B1 publication Critical patent/KR0186008B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/01—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxide ceramics
    • C04B35/10—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxide ceramics based on aluminium oxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/01—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxide ceramics
    • C04B35/46—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxide ceramics based on titanium oxides or titanates
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F05—INDEXING SCHEMES RELATING TO ENGINES OR PUMPS IN VARIOUS SUBCLASSES OF CLASSES F01-F04
    • F05C—INDEXING SCHEME RELATING TO MATERIALS, MATERIAL PROPERTIES OR MATERIAL CHARACTERISTICS FOR MACHINES, ENGINES OR PUMPS OTHER THAN NON-POSITIVE-DISPLACEMENT MACHINES OR ENGINES
    • F05C2201/00—Metals
    • F05C2201/02—Light metals
    • F05C2201/021—Aluminium

Abstract

내용 없음

Description

알루미늄 티타네이트를 기본으로 하는 소결된 세라믹 재료, 이의 제조방법 및 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (20)

  1. 도핑된 알루미늄 티타네이트 및 멀라이트를 포함하고: AI20350내지 61.5중량%, Ti0236내지 47.5중량%,및 Si022.5내지 5중량% (상기 세 성분들의 전체 합은 100%이하이다) , MgO 0.3내지 1중량%및 불순물 1중량%이하의 조성을 갖는 소결된 세라믹재료.
  2. 제1항에 있어서, MgO 함량이 0.3내지 0.6중량%인 소결된 세라믹재료.
  3. 제1항 또는 제2항에 있어서, Fe2030.015내지 0.5중량%를 추가로 함유하는 소결된 세라믹재료.
  4. 제3항에 있어서, Fe203함량이 0.05내지 0.4중량%인 소결된 세라믹재료
  5. 제3항에 있어서, MgO : Fe203중랑%비가 2내지 20인 소결된 세라믹재료.
  6. 제1항에 있어서, Fe2030.015내지 0.5중량%를 추가로 함유하는 소결된 세라믹재료.
  7. 제6항에 있어서, Fe203함량이 0.05내지 0.4중량%인 소결된 세라믹재료.
  8. 제6항에 있어서, MgO : Fe203중랑%비가 2내지 20인 소결된 세라믹재료.
  9. 제1항에 있어서, 소결 후의 미반응 AI203와TiO2함랑의 전체 합이 5중량%이하, 바람직하게는 2.5중량%이하인 소결된 세라믹재료.
  10. 제1항에 따른 조성물을 혼합, 성형 및 소결시키는 단계들을 포함하여 소결된 세라믹재료를 제조하는 방법에 있어서, 세라믹재료를 1,250내지 1,600℃에서 0.5내지 100시간의 체류시간에 걸쳐 소결시키는 단계를 특징으로 하는 방법.
  11. 제10항에 있어서, 소결온도가 1내지 50시간의 체류시간에 걸쳐서 1,300내지 1,470℃인 방법
  12. 제10항에 있어서, 1단계로서 성분들을 개별적으로 또는 혼합물 형태로 습식분쇄시켜 미리 분산시킨 후,습식분쇄된 성분들을 혼합물을 입상화 건조시켜 가공하는 방법.
  13. 10항에 있어서, 소결된 세라믹재료를 반응-소결하는 방법.
  14. 제10항에 있어서, 마그네슘 화합물을 Mg2TiO4, MgTi203, MgTi205또는 이들의 혼합물인 마그네슘 티타네이트로서 조성물에 도입시키는 방법.
  15. 제10항에 있어서, 철 화합물을 미세하게 분산된α-Fe203분말 형태. 철-함유 층 실리케이트 형태 또는 철-함유 점토 또는 카올린 형태로 조성물에 도입시키는 방법.
  16. 제1항에 따른 소결된 세라믹재료의 금속/세라믹 복합재로 이루어진 중공 튜브 형태의 성형품.
  17. 각각 제1항중 따른 소결된 세라믹재료로 이루어진 피스톤, 실린더 헤드. 및 촉매중의 혼입 소재를 포함하는 내부연소 엔진부품.
  18. 제1항에 따른 소결된 세라믹재료로 이루어진 촉매 지지체.
  19. 제1항에 따른 소결된 세라믹재료로 이루어진 유체용 또는 가스용 필터.
  20. 제19항에 있어서, 디젤엔진내의 입자 필터인 필터.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019910010287A 1990-06-22 1991-06-21 알루미늄 티타네이트를 기본으로 하는 소결된 세라믹 재료, 이의 제조방법 및 용도 KR0186008B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE4019892A DE4019892A1 (de) 1990-06-22 1990-06-22 Neue xanthinderivate
DEP4019862.6 1990-06-22
DEP40291669 1990-09-14
DEP4029166.9 1990-09-14

Publications (2)

Publication Number Publication Date
KR920000662A true KR920000662A (ko) 1992-01-29
KR0186008B1 KR0186008B1 (ko) 1999-04-15

Family

ID=6408865

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910010287A KR0186008B1 (ko) 1990-06-22 1991-06-21 알루미늄 티타네이트를 기본으로 하는 소결된 세라믹 재료, 이의 제조방법 및 용도

Country Status (7)

Country Link
US (1) US5641784A (ko)
EP (1) EP0487673A1 (ko)
JP (1) JPH05501265A (ko)
KR (1) KR0186008B1 (ko)
CA (1) CA2064742A1 (ko)
DE (1) DE4019892A1 (ko)
WO (1) WO1992000297A1 (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100335393B1 (ko) * 2000-02-09 2002-05-06 한상목 알루미늄 티타네이트와 점토의 복합체를 이용한 적외선 방사체의 제조방법

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565566A (en) * 1987-04-24 1996-10-15 Discovery Therapeutics, Inc. N6 -substituted 9-methyladenines: a new class of adenosine receptor antagonists
US5290782A (en) * 1989-09-01 1994-03-01 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
CA2061544A1 (en) * 1991-02-25 1992-08-26 Fumio Suzuki Xanthine compounds
EP0541120B1 (en) * 1991-11-08 1999-05-26 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives for the treatment of dementia
IT1260444B (it) * 1992-01-24 1996-04-09 Mario Brufani Derivati della 8-(1-amminocicloalchil)1,3-dialchilxantina, procedimenbto di preparazione e loro composizioni farmaceutiche antidepressive, nootropiche e psicostimolanti
US5336769A (en) * 1992-02-17 1994-08-09 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
CA2093403C (en) * 1992-04-08 1999-08-10 Fumio Suzuki Therapeutic agent for parkinson's disease
US5484920A (en) * 1992-04-08 1996-01-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease
WO1994003173A1 (de) * 1992-08-01 1994-02-17 Boehringer Ingelheim Kg Verwendung von 8-(3-oxocyclopentyl)-1,3-dipropyl-7h-purin-2,6-dion zur symptomatischen behandlung der zystischen fibrose
TW252044B (ko) * 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
DE4236331A1 (de) * 1992-10-28 1994-05-05 Boehringer Ingelheim Kg Synergistische Kombination
ES2120025T3 (es) * 1993-02-26 1998-10-16 Merrell Pharma Inc Derivados de xantina utilizados como antagonistas de receptores de adenosina a1.
JPH08509977A (ja) * 1993-05-06 1996-10-22 メレルダウファーマスーティカルズ インコーポレイテッド 選択的アデノシン受容体剤としての８−置換キサンチン類
DE4316576A1 (de) * 1993-05-18 1994-11-24 Boehringer Ingelheim Kg Verbessertes Verfahren zur Herstellung von 1,3-Dipropyl-8-(3-Oxocyclopentyl)-xanthin
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
US5736528A (en) * 1993-10-28 1998-04-07 University Of Florida Research Foundation, Inc. N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists
US5789416B1 (en) * 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
US5834458A (en) * 1996-10-09 1998-11-10 Eli Lilly And Company Heterocyclic compounds and their use
DE19816857A1 (de) * 1998-04-16 1999-10-21 Boehringer Ingelheim Pharma Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US6576619B2 (en) 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6815446B1 (en) 1999-08-31 2004-11-09 Vanderbilt University Selective antagonists of A2B adenosine receptors
JP3914434B2 (ja) * 1999-08-31 2007-05-16 ヴァンダービルト ユニヴァーシティ Ａ２ｂアデノシン受容体の選択的アンタゴニスト
WO2001034604A2 (en) * 1999-11-12 2001-05-17 Biogen, Inc. Adenosine receptor antagonists and methods of making and using the same
MEP42208A (en) * 1999-11-12 2011-02-10 Biogen Idec Inc Polycycloalkylpurines as adenosine receptor antagonists
AU2001238665A1 (en) 2000-02-23 2001-09-03 Cv Therapeutics, Inc. Method of identifying partial agonists of the a2a receptor
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US20080318983A1 (en) * 2001-11-09 2008-12-25 Rao Kalla A2b adenosine receptor antagonists
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7125993B2 (en) * 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
AU2002359365B2 (en) 2001-11-09 2008-07-10 Gilead Sciences, Inc. A2B adenosine receptor antagonists
WO2004009091A1 (en) * 2002-06-17 2004-01-29 Glaxo Group Limited Purine derivatives as liver x receptor agonists
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
US20050020915A1 (en) 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
EP1524984A1 (en) 2002-07-29 2005-04-27 Cv Therapeutics, Inc. Myocardial perfusion imaging using a2a receptor agonists
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
US20060293312A1 (en) * 2003-04-25 2006-12-28 Howard Dittrich Method of improved diuresis in individuals with impaired renal function
NZ543109A (en) * 2003-04-25 2008-06-30 Novacardia Inc Method of improved diuresis in individuals with impaired renal function
BRPI0509753A (pt) * 2004-04-16 2007-10-16 Novacardia Inc composição farmacêutica e método de tratamento de doença cardiovascular
RU2385322C2 (ru) * 2004-09-01 2010-03-27 Си Ви Терапьютикс, Инк. Способ заживления ран с применением антагонистов аденозинового рецептора a2b
KR20070083714A (ko) 2004-10-20 2007-08-24 씨브이 쎄러퓨틱스, 인코포레이티드 Ａ2ａ 아데노신 수용체 작용제의 용도
PL1989214T3 (pl) 2006-02-03 2017-07-31 Gilead Sciences, Inc. Proces otrzymywania agonisty receptora adenozynowego a2a i jego polimorfów
EP2035009A1 (en) * 2006-06-16 2009-03-18 Novacardia, Inc. Prolonged improvement of renal function comprising infrequent administration of an aa1ra
WO2008028140A1 (en) * 2006-09-01 2008-03-06 Cv Therapeutics, Inc. Methods and compositions for increasing patient tolerability during myocardial imaging methods
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
JP2011502101A (ja) * 2006-09-29 2011-01-20 ギリアード・パロ・アルト・インコーポレイテッド 肺疾患の病歴を有する患者における心筋画像化法
JP2010515081A (ja) * 2007-01-03 2010-05-06 ギリアード・パロ・アルト・インコーポレイテッド 心筋灌流画像化
US20090197900A1 (en) * 2007-03-29 2009-08-06 Howard Dittrich Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
US20080242684A1 (en) * 2007-03-29 2008-10-02 Howard Dittrich Methods of administration of adenosine a1 receptor antagonists
JP2012504147A (ja) * 2008-09-29 2012-02-16 ギリアード サイエンシーズ， インコーポレイテッド 多検出器型コンピュータ断層撮影法において使用するための心拍数コントロール薬およびＡ−２−α受容体作動薬の組み合わせ
KR101110368B1 (ko) * 2010-04-30 2012-02-15 한국세라믹기술원 내열 충격저항성 산화물 소결체 및 그 제조방법
SG10201610936RA (en) 2011-12-22 2017-02-27 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3624215A (en) * 1970-06-25 1971-11-30 Abbott Lab 8-substituted theophyllines as anti-anxiety agents
US4061753A (en) * 1976-02-06 1977-12-06 Interx Research Corporation Treating psoriasis with transient pro-drug forms of xanthine derivatives
FR2531085A1 (fr) * 1982-07-28 1984-02-03 Adir Nouveaux derives de la xanthine, leur procede de preparation et les compositions pharmaceutiques les renfermant
US4612315A (en) * 1984-10-26 1986-09-16 The United States Of America As Represented By The Department Of Health And Human Services Biologically-active 1,3-dipropyl-8-phenylxanthine derivatives
DE3525801A1 (de) * 1985-07-19 1987-01-22 Hoechst Ag Tertiaere hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung
US4755517A (en) * 1986-07-31 1988-07-05 Warner-Lambert Company Derivatives of xanthine, pharmaceutical compositions and methods of use therefor
DE8817122U1 (ko) * 1988-12-22 1993-02-04 Boehringer Ingelheim Kg, 6507 Ingelheim, De
JP2843634B2 (ja) * 1989-03-06 1999-01-06 協和醗酵工業株式会社 キサンチン誘導体
US5290782A (en) * 1989-09-01 1994-03-01 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100335393B1 (ko) * 2000-02-09 2002-05-06 한상목 알루미늄 티타네이트와 점토의 복합체를 이용한 적외선 방사체의 제조방법

Also Published As

Publication number Publication date
WO1992000297A1 (de) 1992-01-09
US5641784A (en) 1997-06-24
JPH05501265A (ja) 1993-03-11
EP0487673A1 (de) 1992-06-03
CA2064742A1 (en) 1991-12-23
KR0186008B1 (ko) 1999-04-15
DE4019892A1 (de) 1992-01-02

Similar Documents

Publication Publication Date Title
KR920000662A (ko) 알루미늄 티타네이트를 기본으로 하는 소결된 세라믹 재료, 이의 제조방법 및 용도
US4327188A (en) Multicellular monolithic ceramic body and preparation thereof
JP2943937B2 (ja) 低熱膨脹性きん青石ハニカム構造物およびその製造方法
DE69830852T2 (de) Verfahren zum brennen von keramischen wabenkörpern
DE2750290A1 (de) Feuerfestartikel und metall-keramikverbundkoerper aus silikathaltigem aluminiumtitanat
CA1131262A (en) Low-expansion ceramics and method of producing the same
JPH0121111B2 (ko)
KR930016376A (ko) 디젤분진필터용 다공성 세라믹의 제조방법
DE2503271A1 (de) Schaeumbare keramische massen
JP2520275B2 (ja) チタン酸アルミニウムセラミツク
US5288672A (en) Ceramics based on aluminum titanate, process for their production and their use
KR950701301A (ko) 세라믹물과 그 제조방법
KR920000659A (ko) 마그네시아-알루미나계 스피넬(spinel)클링커(clinker) 및 이것을 사용한 내화물의 제조법
EP0339379A1 (de) Sinterformkörper auf Basis von Aluminiumtitanat, Verfahren zu ihrer Herstellung sowie deren Verwendung
US4596781A (en) Tough Si3 N4 composite ceramics
KR19980014400A (ko) 알루미늄 티타네이트 원료과립 및 세라믹스의 제조방법
JPH01170744A (ja) ピストン、シリンダヘツド等の内燃機関のエンジン部品
DE959423C (de) Vorrichtung zur Verbrennung von fluessigen und festen Brennstoffen, insbesondere in Strahltriebwerken od. dgl.
SU881077A1 (ru) Шихта дл изготовлени керамических изделий
JPH0829977B2 (ja) 高強度・低熱膨張セラミック及びその製造方法
JPH054859A (ja) リン酸ジルコニウムセラミツクス材料及びその製造方法
JPH04280863A (ja) 高強度低熱膨張セラミックス
JPH0761862A (ja) アルミニウムチタネート焼結体およびその製造方法
SU1758039A1 (ru) Масса дл изготовлени газопроницаемых изделий
JPH0551250A (ja) 低熱膨張セラミツク材料及びその製造法

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J201 Request for trial against refusal decision
B701 Decision to grant
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee